Oncocyte Corporation
15 Cushing
Irvine, California 92618
April 4, 2025
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Alan Campbell
| Re: | Oncocyte Corporation Registration Statement on Form S-1 Originally filed on March 28, 2025 File No. 333-286251 (the “Registration Statement”) Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Oncocyte Corporation (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:00 p.m., Eastern Time, on April 7, 2025, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Jayun Koo, Esq. at (212) 835-4823.
| Very truly yours, | ||
| Oncocyte Corporation | ||
| By: | /s/ Josh Riggs | |
| Josh Riggs | ||
| President and Chief Executive Officer | ||
cc: Jayun Koo, Esq., Haynes and Boone, LLP